Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer. Clinical nuclear medicine Sanli, Y., Zukotynski, K., Mittra, E., Chen, D. L., Nadel, H., Niederkohr, R. D., Subramaniam, R. M. 2018; 43 (12): e439–e452

Abstract

There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.

View details for PubMedID 30394934